Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 57.57 -0.08 (-0.14%) Streaming Delayed Price Updated: 3:04 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Why NASDAQ:SNY provides a good dividend, while having solid fundamentals. December 12, 2023 Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. Via Chartmill Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company December 07, 2023 Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. Via Benzinga Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities December 07, 2023 Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus Via Benzinga IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies December 06, 2023 IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... Via Benzinga Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis December 06, 2023 Merck KGaA (OTC: MKGAF) (OTC: Via Benzinga Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. December 06, 2023 SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill How Is The Market Feeling About Sanofi? November 30, 2023 Via Benzinga Is NASDAQ:SNY a Good Fit for Dividend Investing? November 21, 2023 Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? Via Chartmill Looking Into Sanofi's Recent Short Interest November 13, 2023 Via Benzinga Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift December 05, 2023 Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget. Via Benzinga Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers December 01, 2023 European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... Via Benzinga Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment November 30, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire 2 Biotech Stocks You Can Buy and Hold for the Next Decade November 30, 2023 These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. Via The Motley Fool This Stock Just Dropped By 15%: Is It a Buy? November 03, 2023 Now could be a great opportunity to buy low. Via The Motley Fool Is NASDAQ:SNY a Good Fit for Dividend Investing? October 31, 2023 Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? Via Chartmill Teva Pharma is the way to play the re-rise of generic drugs November 28, 2023 Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth Via MarketBeat Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales November 27, 2023 Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. Via Investor's Business Daily Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder November 27, 2023 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... Via Benzinga Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease November 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst November 22, 2023 Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the Via Benzinga US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges November 17, 2023 The U.S. Via Benzinga Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B November 16, 2023 Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... Via Benzinga Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. November 15, 2023 SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals. Via Chartmill MarketBeat Week in Review – 11/6 - 11/10 November 11, 2023 Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Pfizer and Sanofi shares fall, which one to scoop up? November 07, 2023 Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows Via MarketBeat Exposures COVID-19 Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi November 06, 2023 The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. Via Investor's Business Daily Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 Via Investor Brand Network Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END Via FinancialNewsMedia Investor patience tested as pharmaceutical stocks take a tumble November 01, 2023 The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector Via MarketBeat Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today? October 30, 2023 MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.